Comparison of Viral Hepatitis-Associated Hepatocellular Carcinoma Due to HBV and HCV - Cohort from Liver Clinics in Pakistan

  • 발행 : 2014.10.11


Background: Hepatocellular carcinoma (HCC) is the first cause of death in cirrhotic patients, mostly due to viral hepatitis with HCV or HBV infection. This study was performed to estimate the true prevalence of viral hepatitis-related HCC and the demographic and clinical-pathological associations with the two virus types. Materials and Methods: This cross sectional observational study enrolled clinical data base of 188 HCC patients and variables included from baseline were age, sex, area of residence, clinical-pathological features such as underlying co-morbidity, presence or absence of liver cirrhosis, macrovascular involvement, tumor extension and metastasis, liver lobes involved, serum alpha-fetoprotein level, and hepatitis serologies. Results: Overall prevalence of HCV- and HBV-related HCC was 66.0% and 34.0%, respectively. Patients with HCV were more likely to develop HCC at advanced age ($52.4{\pm}11.9$ vs. $40.7{\pm}12.09$ years), with highly raised serum AFP levels (${\geq}400ng/ml$) 78.2% (HBV 67.1%), large tumor size (HCV-66% >5 cm, HBV-59.3%), and presence of portal vein thrombosis (8.06%, HBV 1.56%). A binominal multivariate analysis showed that HCV-HCC group were more likely to be cirrhotic (OR=0.245, 95%CI: 0.117, 0.516) and had more than two times higher rate of solitary macrovascular involvement (OR=2.533, 95%CI: 1.162, 5.521) as compared with HBV associated HCC. Conclusions: Statistically significant variations were observed from baseline to clinical-pathological characteristics in HCV vs HBV associated HCC. Our study suggests prompt and early screening for high risk patients so that the rate of progression of these chronic viral diseases to cirrhosis and cancer can be decreased.


  1. Abbas Z (2013). Hepatocellular carcinoma in Pakistan. J Coll Physicians SurgPak, 23, 769-770.
  2. Ali S, Ahmad A, Khan RS et al (2014). Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in mardan, pakistan. Adv Virol, 2014, 606201.
  3. Ayub A, Ashfaq UA, Haque A (2013). HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int, 2013, 810461.
  4. Blonski W, Kotlyar DS, Forde KA (2010). Non-viral causes of hepatocellular carcinoma. World J Gastroenterol, 16, 3603-15.
  5. Bosan A, Qureshi H, Bile KM, et al (2010). A review of hepatitis viral infections in Pakistan. Pak Med Assoc, 60, 1045-58.
  6. Brechot C, Kremsdorf D, Soussan P, et al (2010). Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol, 58, 278-87.
  7. Bruix J, Sherman, M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.
  8. Butt AS, Abbas Z, Jafri W (2012). Hepatocellular carcinoma in pakistan: where do we stand? Hepat Mon, 12, 6023.
  9. Butt AS, Hamid S, Wadalawala AA, et al (2013). Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma. BMC Res Notes, 6, 137.
  10. Chan HL, Hui AY, Wong ML, et al (2004). Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-8.
  11. Davis GL, Dempster J, Meler JD, et al (2008). Hepatocellular carcinoma: management of an increasingly common problem. Proc Bayl Univ Med Cent, 21, 266-80.
  12. Di Bisceglie AM (2009). Hepatitis B and hepatocellular carcinoma. Hepatology, 49, 56-60.
  13. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27.
  14. Fan JH, Wang JB, Jiang Y, et al (2013). Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev, 14, 7251-6.
  15. Haddock R, Paulino Y, Bordallo R (2013). Viral hepatitis and liver cancer on the island of guam. Asian Pac J Cancer Prev, 14, 3175-6.
  16. Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG (2013). Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol Lett, 5, 1087-92.
  17. Hiotis SP, Rahbari NN, Villanueva GA, et al (2012). Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol, 12, 64.
  18. Hussain K, El-Serag HB (2009). Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol, 55, 123-38.
  19. Kao WY, Su CW, Chau GY, et al (2011). A comparison of prognosis between patients with hepatitis B and C virusrelated hepatocellular carcinoma undergoing resection surgery. World J Surg, 35, 858-67.
  20. Khan A, Tanaka Y, Azam Z, et al (2009). Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol, 81, 1189-97.
  21. Kikuchi L, Oliveira CP, Carrilho FJ (2014). Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int, 2014, 106247.
  22. Lavanchy D (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107.
  23. Lopez JB, Balasegaram M, Thambyrajah V, Timor J (1996). The value of liver function tests in hepatocellular carcinoma. Malays J Pathol, 18, 95-99.
  24. Michielsen PP, Francque SM, Van Dongen JL (2005). Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol, 3, 27.
  25. Naqi N, Ahmad S, Murad S, Khattak J (2014). Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study. Hematol Oncol Stem Cell Ther, 7, 27-31.
  26. Okamoto E (2013). Cohort analysis of incidence/mortality of liver cancer in Japan through logistic curve fitting. Asian Pac J Cancer Prev, 14, 5891-3
  27. Okonkwo UC, Nwosu MN, Ukah C, Okpala OC, Ahaneku JI (2011). The clinical and pathological features of hepatocellular carcinoma in Nnewi, Nigeria. Niger J Med, 20, 366-71.
  28. Parikh S, Hyman D (2007). Hepatocellular cancer: a guide for the internist. Am J Med, 120, 194-202.
  29. Parkin DM, Bray F, Ferlay J, Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6.
  30. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973). Transection of the oesophagus for bleeding oesophageal varices. Br J Surg, 60, 646-9.
  31. Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU (2010). Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J, 16, 15-23.
  32. Raza SA, Clifford GM, Franceschi S (2007). Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer, 96, 1127-34.
  33. Rehman K, Khan AA, Haider Z, et al (1996). Prevalence of seromarkers of HBV and HCV in health care personnel and apparently healthy blood donors. J Pak Med Assoc, 46, 152-4.
  34. Ryder SD (2003). Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut, 52, 1-8.
  35. Sarwar S, Khan AA, Tarique S (2014). Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis. J Coll Physicians Surg Pak, 24, 18-22.
  36. Shaheen AA, Myers RP (2007). Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology, 46, 912-21.
  37. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006). Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, 28, 112-25.
  38. Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60.
  39. Tanizaki H, Ryu M, Kinoshita T, et al (1997). Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma. Jpn J Clin Oncol, 27, 67-70.
  40. Venook AP, Papandreou C, Furuse J, De Guevara LL (2010). The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist, 4, 5-13.
  41. Yeo Y, Gwack J, Kang S, et al (2013). Viral hepatitis and liver cancer in Korea: an epidemiological perspective. Asian Pac J Cancer Prev, 14, 6227-31.

피인용 문헌

  1. Genotypes of Hepatitis C Virus in Relapsed and Non-respondent Patients and their Response to Anti-Viral Therapy in District Mardan, Khyber Pakhtunkhawa, Pakistan vol.16, pp.3, 2015,
  2. Preparation and Characterization of Anti-GP73 Monoclonal Antibodies and Development of Double-antibody Sandwich ELISA vol.16, pp.5, 2015,
  3. CYP2C19 Genotype Could be a Predictive Factor for Aggressive Manifestations of Hepatocellular Carcinoma Related with Chronic Hepatitis B Infection in Thailand vol.16, pp.8, 2015,
  4. Incidence of Active HCV infection amongst Blood Donors of Mardan District, Pakistan vol.17, pp.1, 2016,
  5. Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data vol.22, pp.4, 2016,
  6. Hepatitis C Virus and Interferon-Free Antiviral Therapeutics Revolution: Implications for Pakistan vol.30, pp.4, 2017,
  7. SAC3D1: a novel prognostic marker in hepatocellular carcinoma vol.8, pp.1, 2018,